<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) is an endogenous insulinotropic <z:chebi fb="7" ids="16670">peptide</z:chebi> secreted from the gastrointestinal tract in response to food intake </plain></SENT>
<SENT sid="1" pm="."><plain>It enhances pancreatic islet beta-cell proliferation and <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulin secretion, and lowers blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and food intake in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="2" pm="."><plain>A long-acting GLP-1 receptor (GLP-1R) <z:chebi fb="4" ids="48705">agonist</z:chebi>, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the <z:mp ids='MP_0008912'>nervous</z:mp> system of rodents and humans, where receptor activation elicits neurotrophic actions </plain></SENT>
<SENT sid="4" pm="."><plain>We detected GLP-1R <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons </plain></SENT>
<SENT sid="5" pm="."><plain>These cells are vulnerable to <z:mp ids='MP_0005039'>hypoxia</z:mp>- and 6-hydroxydopamine-induced cell <z:hpo ids='HP_0011420'>death</z:hpo>, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="8" pm="."><plain>Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved <z:chebi fb="40" ids="18243">dopamine</z:chebi> levels, and improved motor function in the <z:chebi fb="0" ids="17963">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</z:chebi> (MPTP) mouse model of <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> </plain></SENT>
</text></document>